Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haige Ye

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Clinical Epigenetics|March 26, 2024
Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclaxDanyang Li, Yigang Yuan, Chen Meng, et al.
Cellular & Molecular Biology Letters|January 13, 2021
Iron overload adversely effects bone marrow haematogenesis via SIRT-SOD2-mROS in a process ameliorated by curcuminShujuan Zhou, Lan Sun, Shanhu Qian, et al.
Theranostics|January 3, 2023
DNA hypermethylation-induced miR-182 silence targets BCL2 and HOXA9 to facilitate the self-renewal of leukemia stem cell, accelerate acute myeloid leukemia progression, and determine the sensitivity of BCL2 inhibitor venetoclaxSisi Ye, Fang Xiong, Xiaofei He, et al.
The Oncologist|April 15, 2017
Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell LymphomaHun Ju Lee, Jorge E Romaguera, Lei Feng, et al.
International Journal of Cancer|May 19, 2023
Treatment patterns and clinical outcomes of mantle cell lymphoma: A retrospective cohort study by CHOICEDongfeng Zeng, Yu Fang, Yue Fei, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Clinical Epigenetics|March 26, 2024
Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclaxDanyang Li, Yigang Yuan, Chen Meng, et al.
Cellular & Molecular Biology Letters|January 13, 2021
Iron overload adversely effects bone marrow haematogenesis via SIRT-SOD2-mROS in a process ameliorated by curcuminShujuan Zhou, Lan Sun, Shanhu Qian, et al.
Theranostics|January 3, 2023
DNA hypermethylation-induced miR-182 silence targets BCL2 and HOXA9 to facilitate the self-renewal of leukemia stem cell, accelerate acute myeloid leukemia progression, and determine the sensitivity of BCL2 inhibitor venetoclaxSisi Ye, Fang Xiong, Xiaofei He, et al.
The Oncologist|April 15, 2017
Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell LymphomaHun Ju Lee, Jorge E Romaguera, Lei Feng, et al.
International Journal of Cancer|May 19, 2023
Treatment patterns and clinical outcomes of mantle cell lymphoma: A retrospective cohort study by CHOICEDongfeng Zeng, Yu Fang, Yue Fei, et al.
Pageof 5